Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer

• DOI: 10.1016/j.clbc.2024.06.006
• Publication Date: 2024-06-19T07:13:40Z
• Authors: Antoine El Kaddissi; Dewi Vernerey; Antoine Falcoz; Laura Mansi; Fernando Bazan; Loïc Chaigneau; Erion Dobi; Morgan Goujon; Nathalie Meneveau; Marie-Justine Pai...; Zohair Selmani; Julien Viot; Chloé Molimard; Franck Monnien; Anne-Sophie Woronoff; Elsa Curtit; Christophe Borg; Guillaume Meynard
• Keywords: Adult; Receptor, ErbB-2; Breast Neoplasms; Antineoplastic Agents; Ketones; Middle Aged; Prognosis; Progression-Free Survival; Polyether Polyketides; Survival Rate; Humans; Female; France; Furans; Retrospective Studies; Aged

Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patients treated in pivotal clinical trials achieved low survival rates, therefore, the identification of prognostic criteria for long progression-free survival (PFS) is still an unmet medical need. In this study, we sought to determine potential prognostic criteria for long-term eribulin response in HER2-negative MBC.Our retrospective cohort includes female patients with HER2-negative MBC treated with eribulin in Franche-Comté, France. We defined a long-term response as at least 6 months of eribulin treatment. The primary endpoint was the analysis of criteria that differ according to the progression-free survival. Secondary outcomes concerned overall survival and response rate.From January 2011 to April 2020, 431 patients treated with eribulin were screened. Of them, 374 patients were included. Median PFS was 3.2 months (2.8-3.7). Eighty-eight patients (23.5%) had a long-term response to eribulin. Four discriminant criteria allowed to separate PFS in 2 arms (PFS < 3 months or > 6 months) with a 78% positive predictive value: histological grade, absence of meningeal metastasis, response to prior chemotherapy, and OMS status. We have developed a nomogram combining these 4 criteria. Median overall survival was 8.5 months (7.0-9.5).Eribulin response in MBC can be driven by clinical and biological factors. Application of our nomogram could assist in the prescription of eribulin.